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Capsule Summary. Single-cell responses in HLA-B*57:01 abacavir patch test positive skin remote 42 
to the acute hypersensitivity reaction demonstrate polyclonal T-cell activation and proliferation 43 
characterized by a transcriptional and cellular response consistent with memory responses to 44 
altered peptides. 45 
 46 












  59 
To the Editor 60 
 61 
Abacavir is a guanosine analogue used as part of combination antiretroviral therapy for the 62 
treatment of HIV-1 infection.  Abacavir hypersensitivity syndrome (AHS) was the major treatment-63 
limiting toxicity of abacavir characterized by fever, malaise, gastrointestinal and respiratory 64 
symptoms, and a generalized rash that occurs later in 70% of cases.  AHS requires carriage of HLA-65 
B*57:01, providing a 100% negative predictive value and a 55% positive predictive value(1-3).  AHS 66 
is now a preventable disease that has been addressed by routine HLA-B*57:01 screening prior to 67 
abacavir prescription.  Research has shown that abacavir non-covalently binds to the floor of the 68 
peptide binding groove of HLA-B*57:01, thus generating a vastly different immunopeptidome 69 
presented to CD8+ T cells and the concurrent generation of CD8+ T cells with multiple 70 
specificities(4, 5).   71 
 72 
 AHS is a CD8+ T-cell cell dependent reaction and does not elicit an antibody response.   Although 73 
the mechanism by which abacavir alters antigen presentation is understood, the nature of the 74 




 T cells are recruited to the skin in 75 
response to abacavir (6).  Polyclonal HLA-B*57:01-restricted CD8
+
 T-cell responses to abacavir 76 
within the peripheral blood are a feature of AHS(4, 7).  However, it is unknown if this polyclonal 77 
response is a feature of tissue responses to abacavir, or if a restricted subset of T cells is recruited 78 
to sites of inflammation.  Although it is known that HLA-B*57:01-restricted CD8
+
 T cells produce 79 
interferon gamma (IFNγ) and tumour necrosis factor alpha (TNFα) in response to abacavir (7),  the 80 
full functionality of these cells has not been assessed.  Here we combine single cell (sc) T-cell 81 
receptor (TCR) sequencing (scTCRseq) and scRNAseq to define the landscape of abacavir-specific T 82 
cells within a positive skin patch test to abacavir applied fourteen years after AHS.  83 
 84 
A 67 year old HLA-B*57:01 positive man had a history of AHS in February 2002 which was 85 
characterized by onset of headaches, arthralgia, myalgia, fever and nausea 11 days following 86 
commencement of a fixed dose combination of abacavir, lamivudine and zidovudine, and 87 
resolution within 48 hours of discontinuation of all drugs. In March 2002, he commenced and 88 
tolerated zidovudine, lamivudine and efavirenz. In March 2003, CD4+ T cell count was 1080/mm3 89 
(40%) and viral load (VL) 80 copies/ml and abacavir patch tests to 1% and 10% abacavir in 90 
petrolatum were positive. In May 2004, he was changed to zidovudine, lamivudine, lopinavir and 91 
ritonavir due to efavirenz central nervous system side effects.  In April 2005 he was changed to 92 
tenofovir, lamivudine atazanavir/ritonavir due to fat wasting.  In November 2016 he was simplified 93 
to tenofovir, emtricitabine and dolutegravir.   For the last 12 years he had remained stable with 94 
normal CD4+ T cell counts and undetectable viral load.  In July 2017, after informed consent 1% 95 
and 10% abacavir and petrolatum control were applied to the flat surface of the back. The positive 96 
1% and 10% patch tests and unaffected skin distant to the patch tests were biopsied 96 hours 97 
later.  At the time of sampling in July 2017, he remained on tenofovir, emtricitabine and 98 
dolutegravir and CD4+ T cell count was 828/mm
3
 (42%); viral load <40 copies/ml.  T cells were 99 
isolated by collagenase digestion from all biopsies.  CD3
+
 T cells were single cell sorted and 100 
subjected to immediate ex vivo primer-based scTCRseq and scRNAseq.  In addition, T-cell lines 101 
created from the collagenase digested tissue or isolated by explant culture, were exposed to drug 102 
to confirm specificity to abacavir. 103 
 104 
T cells within normal skin were predominantly of the effector memory T-cell (TEM) phenotype 105 
(CD45RO+CCR7-).  In normal skin, CD4+ T cells were the major cell type expressing the skin homing 106 
marker C-C chemokine receptor 10 (CCR10) (52%), the residency marker CD103 (11%); few cells 107 
expressed CD69.  In abacavir-exposed skin, 56% of CD3+ cells were CD4+ T cells. Of these, the 108 
majority (98%) were of the TEM phenotype; 34% expressed CCR10 and the majority were negative 109 
for CD103 and CD69 suggesting recent recruitment to the site.  CD8α was poorly expressed on 110 




 T cells were 111 
both present in explant cultures from 1% abacavir-exposed skin, i.e. those not exposed to 112 
collagenase digestion (Sup. Fig. 1). 113 
 114 
Direct ex vivo single cell sorting and sequencing was employed to map TCR usage and measure the 115 
clonality of abacavir-responsive T cells.  Similar to responses that have been previously 116 
demonstrated to abacavir in the peripheral blood (Sup. Fig. 2), T-cell responses to abacavir in a 117 
positive patch test remote to the acute AHS were highly polyclonal (Fig. 1). Circos plots show 118 
variable T-cell receptor alpha variable (TRAV) and T-cell receptor beta variable (TRBV) gene 119 
expression, with associated joining (TRAJ or TABJ) chain usage for each TCR V alpha and V beta 120 
gene (Fig. 1).  TRAV-26.1, -38, -12.2 and -9.2 were the most common TCR V alpha genes used by T 121 
cells in abacavir-exposed skin, with TRBV20.1 the most common V beta gene.  In normal skin 122 
TRAV30 and TRBV20.1 were the most common V alpha and V beta genes, respectively. 123 
 124 
T cells isolated from the skin of normal and abacavir-exposed skin by collagenase digestion were 125 
used to create T-cell lines using two rounds of non-specific stimulation (phytohemagglutinin P 126 
followed by anti-CD3 treatment).  These lines were tested for specificity to abacavir by IFNγ 127 
enzyme-linked immunospot (ELISpot) assay.  T-cell lines from 1% and 10% abacavir-exposed skin 128 
but not those from normal skin produced IFNγ when exposed to 35 uM of drug (Sup. Fig. 3A).  129 
Similar to what we had demonstrated in non-expanded T-cell populations, bulk TCR sequencing of 130 
the T-cell line from the 1% abacavir-exposed skin showed a highly diverse TCR repertoire (Sup. Fig 131 
3B).  Explant cultured T cells isolated from 1% abacavir-exposed, but not normal skin, proliferated 132 
in culture without additional exogenous stimulation.  This spontaneously expanded line was also 133 
tested for specificity to abacavir. Following stimulation of the T-cell line with abacavir, CD8+ T cells 134 
up-regulated both CD69 and CD137, indicating continued specificity for the drug in culture.  This T-135 
cell line expressed a more restricted, but still, polyclonal TCR repertoire. (Sup. Fig. 1).   136 
 137 
Single cell transcriptional profiling was used to assess the phenotype of T cells in normal versus 138 
abacavir-exposed skin directly ex vivo (Fig. 2).  T cells derived from skin exposed to 1% or 10% 139 
abacavir demonstrated a common transcriptional signature (Fig. 2A) and these data were 140 
therefore pooled for subsequent analysis.  The top 20 differentially regulated genes in abacavir-141 
exposed and non-exposed skin-derived T cells are shown in Figure 2B (see also Sup. Fig. 4).  142 
Differentially expressed genes fall into several categories.  T cells in normal skin were marked by 143 
genes known to be enriched or suppressed in TRM cells and included those that either regulate T-144 
cell migration or commitment to tissue residency such as S1PR1, SELL (L-selectin), CD44 and 145 
DUSP1 (8) .  Genes significantly elevated in T cells from abacavir-exposed skin compared to 146 
abacavir-unexposed, unaffected skin included those involved in T-cell metabolism such as LAT1 (9) 147 
and those involved in T-cell activation and effector function such as superoxide dismutase 2, 148 
interferon-induced transmembrane genes 1 and 2.  The latter two genes regulate immunity to 149 
RNA viruses, including HIV.   A Broad Institute gene set enrichment analysis (GSEA) identified 150 
several hallmark gene sets that were differentially expressed in T cells derived from normal versus 151 
abacavir-exposed skin.  The IFNγ response pathway (p=1.06 x 10-11) and the IFNα response 152 
pathway (p=1.03x 10
-8
), were significantly up-regulated in T cells from abacavir-exposed skin.  In 153 
contrast, in T cells derived from normal skin the TNFα signalling via NFκb pathway (p=9.57 x 10-17) 154 
and the UV response - down pathway (p=2.76 x 10
-8
) were significantly up-regulated.  155 
 156 
Our findings in abacavir-exposed patch test-positive skin in a patient 14 years following acute AHS 157 
are consistent with the altered peptide model of hypersensitivity.  We propose that in keeping 158 
with this model, as applied to the skin patch test, abacavir is taken up by dendritic cells (DC) in the 159 
epidermis and presented to TRM cells.  This interaction leads to endothelial activation and 160 
recruitment of polyclonal TEM to the site of abacavir exposure.  It is also likely that migratory DC 161 
present the antigen to TEM cells in skin- draining lymph nodes and that these TEM lead to additional 162 
populations of polyclonal TEM cells that home to the skin.  Collectively these TEM recognize the 163 
complex of HLA-B*57:01 plus abacavir complexed with self-antigens to form novel structures.  164 
Altered peptide presentation leads to T-cell activation and proliferation and the expression of a 165 
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  198 
Figure legends 199 
 200 
Figure 1.  TCR usage in normal or abacavir exposed skin.  A patient with a prior history of abacavir 201 
hypersensitivity was patch tested with 1 or 10% abacavir for 96 hours.  Each 4 mm punch biopsy, 1 from 202 
normal skin, 1 from 1% abacavir exposed skin and 2 from 10% abacavir exposed skin was digested with 203 
collagenase P.   CD3
+
 cells were single cell sorted and subjected to TCR sequencing.  Shown are TCR variable 204 
and joining chains making up each CDR3 region.  Data are from normal skin and combined data from 1 and 205 
10% abacavir exposed skin.   206 
 207 
Figure 2.  Single cell transcriptional analysis.  A. tSNE plot comparing transcriptional profile of T cells 208 
isolated from normal skin and 1% and 10% abacavir exposed skin.  B. Top 20 differentially expressed genes 209 
in abacavir exposed and normal skin.  Abacavir exposed skin data are combined single cell data from 1% 210 
and 10% abacavir exposed T cells.  211 
 212 
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Supplementary Materials and Methods 
Patch testing and biopsy.  Skin patch tests were prepared and applied in duplicate 
according to the procedure previously reported by Phillips et al. 2002 (1) and were adapted 
to use 1% and 10% concentrations of abacavir and excipient and petrolatum controls 
(Oxford compounding Pty Ltd). Test results were read and recorded at 48 h after application 
and then, because of the large time interval between last patch test exposure to ABC, 14 
years, were re-applied for a further 48 hours. Two biopsies were taken from 1% and 10% 
ABC patch test skin and one biopsy was taken from control patch test, normal skin. 
T cell isolation.  Two 4 mm biopsies from each of the 1% and 10% ABC patch test skin and 
one biopsy from normal skin were collected directly into RPMI plus 10% fetal calf serum 
(FCS) and processed within 30 minutes of collection.  Biopsies were finely minced in 1 ml of 
PBS and then added to 5 ml of 50% T-cell media (TCM, Iscove’s Modified Dulbecco’s 
Medium, 20% FCS, 2mM L-glutamine, 100 Units/ml penicillin, 100 ug/ml of streptomycin 
and 3.4 uM beta 2-mercaptoethanol). 
For enzymatic digestion cells in T-cell media were incubated with 1 mg/ml of collagenase P 
and placed a rotator for 90 minutes at 37°C. DNA was digested by the addition of 200 Kuntz 
units/ml of DNAse I for 15 minutes at 37°C before the cells were strained through a 70 uM 
filter and washed with 25 ml of Hank’s buffered salt solution (HBSS)/HEPES/10 mM EDTA at 
4°C.  Cells were centrifuged at 400 x g and washed with a further 10 ml of PBS.  Skin derived 
T cells were then stained immediately for single cell sorting. 
For the isolation of T cells via explant culture, one 1% abacavir skin biopsy was minced and 
placed in TCM plus 100 units/ml of rIL-2 on a cellfoam matrix grid (Nohla Therapeutics, 
Australia, CY-903) for 2 weeks.  T cells that migrated into the media proliferated without the 
addition of additional stimulation and were frozen as a T cell line.  This line was used to 
assess specificity for abacavir.  200, 000 T cells were cultured overnight in TCM, TCM plus 
20, 000 autologous LCLs or TCM plus 20, 000 autologous LCLs (lymphoblastoid cell line) and 
10 ug/ml of abacavir.  Cells were stained for CD3 (BD, AF700, clone UCHT1), CD4 (BD, 
PerCPCy5.5, clone OKT4), CD8a (Biolegend, APC Fire 750, clone RPA-T8), CD137 (PE, clone 
4B4-1), CD69 (BD, APC, clone FN50), CD103 (BD, PE/Cy7 clone Ber-ACT8), CCR7 (BV421, 
clone 150503), CD45RO (BV510, clone UCHL1) and CCR10 (BB515, clone 1B5). Flow 
cytometry was employed to determine specificity by assessing up-regulation of CD137 and 
CD69. 
T-cell expansion. For cloning of enzymatically extracted T cells, tissues were re-extracted as 
described above for an additional 90 minutes.  Cells extracted from normal and abacavir 
exposed tissues were non-specifically expanded as described previously (2).  Briefly, in a 
single U bottomed well of a 96 well plate, washed T cells were provided with 150, 000 
irradiated allo-feeder cells (PBMCs) and cultured in T-cell cloning medium (RPMI, 5% human 
serum (Sigma-Aldrich), 5% FCS, 2mM L-glutamine, 100 Units/ml penicillin and 100 ug/ml of 
streptomycin) plus PHA to a final concentration of 1.6 ug/ml.  Two days later, and then 
every 2-3 days, cells were supplemented with 10% natural IL-2 (ZeptoMetrix, USA).  Two 
weeks later 50, 000 T cells were further expanded by the addition of anti-CD3 (30 ng/ml of 
OKT3 plus 5 x 10
6
 irradiated (8000 Rad) autologous LCLs and 50 x 10
6
 irradiated (3300 Rad) 
autologous PBMCs in a total volume of 25 ml.  Two days later T cells were provided with 100 
units/ml of rIL-2.  Cells were washed on day 4 to remove anti-CD3 and expanded for an 
additional 10 days with the rIL-2 being replaced every 2-3 days. T cells were frozen until 
required. 
Single cell sorting. Collagenase P purified T cells were stained with CD3 (BD, AF700, clone 
UCHT1), CD4 (BD, PerCPCy5.5, clone OKT4), CD8 (Biolegend, APC Fire 750, clone RPA-T8), 
CD137 (PE, clone 4B4-1), CD69 (BD, APC, clone FN50), CD103 (BD, PE/Cy7 clone Ber-ACT8), 
CCR7 (BV421, clone 150503), CD45RO (BV510, clone UCHL1) and CCR10 (BB515, clone 1B5). 
All antibodies were obtained from Becton Dickinson (BD), Australia, unless otherwise stated. 
Dead cells were excluded with the use of the fixable viable Stain, FVS620 (BD).  Single cells 
were index sorted into 96 well plates on a FACSAria III (Telethon Kids Institute, Perth, 
Australia) directly into 3 ul of reverse transcriptase buffer.  Immediately following sorting 
cells were frozen on dry ice and then plates were stored at -80°C until required. 
Single cell TCR sequencing.  Using our novel TCR/RNAseq platform single cells undergo 
oligodT-primed reverse transcription during which, individual well’s (cell’s) cDNA products 
were barcoded and generically tagged with both 3’ oligo-dT and 5’ biotin labelled template 
switching oligonucleotides (TSO). Subsequent amplification of the cDNA derived from a 
single cell was amplified using the generic tags. Specific transcripts were targeted with a 
combination of nested generic tags and suitable gene specific primers (e.g. TCR alpha or 
beta conserved regions). The transcriptome was analysed using a modified Nextera 
transposon-mediated tagging-and-fragmentation (“tagmentation”) with subsequent 
amplification of the 5’ and 3’ ends of the transcripts between the introduced Nextera-tag 
and the generic tags from cDNA conversion. Samples were multiplexed for next generation 
library preparation and sequencing - single cell sequences are bioinformatically separated. 
IFNγ ELISpot.  ELISpot were performed as previously described (3).  Briefly, 96 well ELISpot 
plates (MultiScreen-IP Filter Plate, Millipore) were coated with 100 ul/well of anti-IFNγ (1-
DIK, 2µg/mL - Mabtech) overnight at 4°C.  Coating antibody was removed by 6x washes in 
200 ul of PBS and the wells blocked with 100 ul of RPMI plus 10% FCS (R10) for 30-180 
minutes at room temperature (RT). 10, 000 to 20, 000 T cells were added to each well in a 
total volume of 100 ul of R10 (RPMI, 10% FCS, 2mM L-glutamine, 100 Units/ml penicillin and 
100 ug/ml of streptomycin).  Autologous LCLs were incubated for 24 hours with 35 uM 
abacavir and then washed 3 times before adding them to T cells.  Cloned skin derived T cells 
were incubated in T cell cloning media plus 10 units/ml of rIL-2 with abacavir pulsed LCLs 
overnight. Controls (anti-CD3-positive control, 100 ul of R10-negative control and pulsed 
LCLs negative control) were treated similarly. Plates were washed as described and 
incubated with 100 ul/well of diluted (1/1000 in PBS/0.5% FCS) biotinylated anti-IFNγ (7-B6, 
Mabtech) at RT for 2 hrs. Plates were washed as described and incubated with 100 ul/well 
of streptavidin horseradish peroxidise (1/1000 in PBS/0.5% FCS) for one hour at RT in the 
dark. Plates were washed as described and developed with 100 ul/well of TMB for 12 
minutes in the dark.  Colour reaction was stopped by 6 washes in water and the plates air 
dried for 24 hrs and read on a plate reader (AID). 
 
Bioinformatics. 3′ and 5’ RNA libraries were sequenced using the 2 x 75 bp paired end 
Illumina NextSeq. Reads for the individual single-cells were demultiplexed using plate id (30 
nt), and cell barcode (6 nt) from either Read 1 or Read 2. The other read was further 
demultiplexed as either 3’ or 5’ using primer sequence (30 nt) and the reminder 45 nt 
sequences were aligned with CLC Bio (v.2018), using the GRCh38 human reference genome 
(Ensembl rel. 92). Gene-specific read counts were calculated using HTSeq-count using latest 
Gencode annotations and the 3’ and 5’ counts were summed. Cells with less than 200 genes 
and more than 5% mitochondrial content were removed. Furthermore, genes with > 0 
counts in fewer than three cells were also removed. Downstream analyses (normalization, 
PCA, differential expression and visualization) were performed in Seurat v.2.3.4 R package 
and Scanpy. TSNE analysis was performed using following settings: theta=0, 
max_iter=10000, perplexity=100.  Differential expression analysis was performed using the 
Wilcoxon rank-sum test. The P values were adjusted for multiple testing using the False 
Discovery Rate (FDR) correction. Pathway analysis was done using MSigDB. 
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